Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease - challenges and perspectives

Current Pharmaceutical Design

Volumn 20, Issue 18, 2014, Pages 3083-3092

  Polidori, Maria Cristina ^a   Nelles, Gereon ^a  

^a NeuroMed MedCampus Hohenlind Cologne   (Germany)

Author keywords

Alzheimer's disease; Antioxidant; Clinical trial; Free radical; Mild cognitive impairment; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; CHOLINESTERASE INHIBITOR; CURCUMIN; DIMEBON; DONEPEZIL; EPIGALLOCATECHIN GALLATE; FLAVONOID; FREE RADICAL; IDEBENONE; LEVACECARNINE; MEMANTINE; MULTIVITAMIN; POLYPHENOL; PRAMIPEXOLE; RESVERATROL; THIOCTIC ACID;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; DEMENTIA; DIET RESTRICTION; DIET SUPPLEMENTATION; GINKGO BILOBA; HUMAN; MEDITERRANEAN DIET; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NUTRITION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; ANIMAL; CLINICAL TRIAL (TOPIC); DIET; PHYSIOLOGY; PROCEDURES;

ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; DIET; HUMANS; MILD COGNITIVE IMPAIRMENT; OXIDATIVE STRESS; RISK FACTORS;

EID: 84903708253     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113196660706     Document Type: Article

References (74)

1. World Alzheimer Report 2010, Alzheimer's Disease International, http://www.alz.co.uk/research/world-report.
2. Reisberg B, Gauthier S. Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer's disease. Intern Psychoger 2008; 20: 1-16.
3. Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia. How to move forward? Neurology 2009; 72: 368-74.
4. Polidori MC, Pientka L. Bridging the pathophysiology of Alzheimer's disease with vascular pathology: the feed-back, the feedforward and oxidative stress. J Alzheimer's Dis 2012; 28: 1-9.
5. Smith MA, Nunomura A, Lee H, et al. Chronological primacy of oxidative stress in Alzheimer's disease. Neurobiol Aging, 26: 579-80.
6. Mariani E, Polidori MC, Cherubini A, Mecocci P. Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 827: 65-75.
7. Polidori MC. Oxidative stress and risk factors of Alzheimer's disease: clues to prevention and therapy. J Alzheimers Dis 2004; 6: 185-91.
8. Salmina AB, Inzhutova AI, Malinovskaya NA, Petrova MM. Endothelial dysfunction and repair in Alzheimer-type neurodegeneration: neuronal and glial control. J Alzheimers Dis 2010; 22: 17-36.
9. Liu D, Pitta M, Lee JH, et al. The KATP channel activator diazoxide ameliorates amyloid-β and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease. J Alzheimers Dis 2010; 22: 443-57.
10. Mamelak M. Sporadic Alzheimer's Disease: the starving brain. J Alzheimer's dis 2012; 31: 459-74.
11. de la Torre JC. Alzheimer's disease: how does it start? J Alzheimers Dis 2002; 4: 497-512.
12. de la Torre JC. Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol Aging 2000; 21: 331-42.
13. Vagnucci AH, Li WW. Alzheimer's disease and angiogenesis. Lancet 2003; 361: 605-8.
14. Sies H, Strategies of antioxidant defense, Eur J Biochem 1993; 215: 213-9.
15. Pratico' D, Polidori MC, Mecocci P. Vitamin E, Dementia, and Cognitive Function. In Hermann W and Obeid R, Eds. Vitamins in the Prevention of Human Diseases. Walter de Gruyter, 2010.
16. Hensley K, Benaksas EJ, Bolli R, et al. New perspectives on vitamin E: gamma-tocopherol and carboxyethylhydroxychroman metabolites in biology and medicine. Free Radic Biol Med 2004; 36: 1-15.
17. Morris MC, EvansDA, Bienias JL, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002; 287: 3230-7.
18. Larrieu S, Latenneur L, Helmer C, Dartigues JF, Barberger-Gateau P. Nutritional factors and risk of incident dementia in the PAQUID longitudinal cohort. J Nutr HealthAging 2004; 8: 150-4
19. Morris MC, Evans DA, Tangney CC, et al. Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. Am J Clin Nutr 2005; 81: 508-14.
20. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of antioxidants and risk of Alzheimer's disease. JAMA 2002; 287: 3223-9.
21. Masaki KH, Losonczy KG, Izmirlian G, et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000; 54: 1265-72.
22. Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS. Vitamin E and cognitive decline in older persons. Arch Neurol 2002; 59: 1125-32.
23. Grodstein F, Chen J, Willett WC. High-dose antioxidant supplements and cognitive function in community-dwelling elderly women. Am J Clin Nutr 2003; 77: 975-84.
24. Zandi PP, Anthony JC, Khachaturian AS, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004; 61: 82-8.
25. Luchsinger JA, Wang MX, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003; 60: 203-8.
26. Yaffe K, Clemons TE, McBee WL, Lindblad AS. Impact of antioxidants, zinc and copper on cognition in the elderly: a randomized, controlled trial. Neurology 2004; 63: 1705-7.
27. Dumont M, Lin MT, Beal MF. Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease. J Alzheimers Dis 2010; 20: S633-S643.
28. Cooney RV, Franke AA, Harwood PJ, Hatch-Pigott V, Custer LJ, Mordan L. γ-Tocopherol detoxification of nitrogen dioxide: Superiority to α-tocopherol. Proc Natl Acad Sc U S A 1993; 90:1771-5.
29. Hensley K, Barnes LL, Christov A, et al. Analysis of postmortem ventricular cerebrospinal fluid from patients with and without dementia indicates association of vitamin E with neuritic plaques and specific measures of cognitive performance. J Alzheimers Dis. 2011; 24: 767-74.
30. Polidori MC, Stahl W, Sies H, Brigelius-Flohe R. Vitamin E, metabolism and biological activity of metabolic products. In Preedy V and Watson R, Eds. The Encyclopedia of Vitamin E. New York: CAB International 2007, pp. 11-20.
31. Sung S, Yao Y, Uryu K, et al. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J 2004; 18: 323-5.
32. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997; 336: 1216-22.
33. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. New Engl J Med 2005; 52: 2379-88.
34. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008; 65: 1631-52.
35. Baum L, Lam CW, Cheung SK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer's disease. J Clin Psychopharmacol 2008; 28: 110-3.
36. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2005; 2: 131-6.
37. Ringman GM, Cole GM, Tend E. Oral curcumin for the treatment of mild-to-moderate Alzheimer's disease: tolerability and clinical and biomarker efficacy results of a placebo-controlled 24-week study, Proceedings of the International Conference of Alzheimer's disease 2008, Chicago, abstract.
38. Spencer JP. Beyond antioxidants: the cellular and molecular interactions of flavonoids and how these underpin their actions on the brain. Proc Nutr Soc 2010; 69: 244-60.
39. Lotito SB, Frei B. Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon? Free Radic Biol Med 2006; 41: 1727-46.
40. Mecocci P, Polidori MC. Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochim Biophys Acta 2012; 1822: 631-8.
41. Morillas-Ruiz JM, Rubio-Perez JM, Albaladejo MD, Zafrilla P, Parra S, Vidal-Guevara ML. Effect of an antioxidant drink on homocysteine levels in Alzheimer's patients. J Neurol Sci 2010; 299: 175-8.
42. Kennedy DO, Wightman EL, Reay JL, et al. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr 2010; 91: 1590-7.
43. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia., Cochrane Database Syst Rev 2009; 1: CD003120.
44. De Kosky ST, Fitzpatrick A, Ives DG, et al. The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp Clin Trials 2006; 27: 238-53.
45. Snitz BE, O'Meara ES, Carlson MC, et al. Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 2009; 302: 2663-70.
46. Andrieu S, Ousset PJ, Coley N, Ouzid M, Mathiex-Fortunet H, Vellas B and the GuidAge study Group, GuidAge study: a 5-year double-blind, randomized trial of EGb 761 for the prevention of Alzheimer's disease in elderly subjects with memory complaints. i. rationale, design and baseline data. Curr Alzheimer Res 2008; 5: 406-15.
47. Dumont M, Beal MF. Neuroprotective strategies involving ROS in Alzheimer's disease. Free Radic Biol Med 2011; 51: 1014-26.
48. Su B, Wang X, Bonda D, Perry G, Smith M, Zhu X. Abnormal mitochondrial dynamics-a novel therapeutic target for Alzheimer's disease? Mol Neurobiol 2010; 41: 87-96.
49. Doody RS, Gavrilova SI, Sano M, et al. Effect of dimebon on cognition, activities of daily living, behavious, and global function in patients with mild-to-moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled study. Lancet 2008; 372; 207-15.
50. Jones RW. Dimebon disappointment. Alzheimers Res Ther 2010; 2: 25.
51. Thal LJ, Grundman M, Berg J, et al. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. Neurology 2003; 61: 1498-502.
52. Polidori MC, De Spirt S, Stahl W, Pientka L. Conflict of evidence: carotenoids and other micronutrients in the prevention and treatment of cognitive impairment. Biofactors 2012; 38: 167-71.
53. Mecocci P, Mariani E, Cornacchiola V, Polidori MC. Antioxidants for the treatment of mild cognitive impairment. Neurol Res. 2004; 26: 598-602.
54. Mecocci P., Mariani E, Polidori MC, Hensley K, Butterfield DA. Antioxidant agents in Alzheimer's Disease. Centr Nerv Syst Agents Med Chem 2008; 8: 48-63.
55. Kamat CD, Gadal S, Mhatre M, Williamson KS, Pye QN, Hensley K. Antioxidants in central nervous system diseases: preclinical promise and translational changes. J Alzheimer's Dis 2008; 15: 473-93.
56. Dumont M, Lin MT, Beal MF. Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease. J Alzheimer's dis. 2010; 20: S633-S643.
57. Stahl W, van den Berg H, Arthur J, et al. Bioavailability and metabolism. Mol Aspects Med. 2002; 23: 39-100.
58. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States 2000. JAMA 2004; 291: 1238-45.
59. Shatenstein B, Kergoat MJ, Reid I, Chicoine ME. Dietary intervention in older adults with early-stage Alzheimer dementia: early lessons learned. J Nutr Health Aging 2008; 12: 461-9.
60. Biofactors and Cognitive Functions. Polidori MC, Guest Ed. Bio-Factors, Volume 38, Number 2 March/April 2012.
61. Anlasik T, Sies H, Griffiths HR, Stahl W, Polidori MC. Dietary habits are major determinants of the plasma antioxidant status in healthy elderly subjects. Br J Nutr 2005; 94: 639-42.
62. Polidori MC, Carrillo JC, Verde PE, Stahl W, Sies H, Siegrist J. Plasma micronutrient status is improved after a 3-month dietary intervention with 5 daily portions of fruits and vegetables: implications for optimal antioxidant levels. Nutrition Journal 2009; 8: 10-1.
63. Polidori MC, Stahl W, Eichler O, Niestroj I, Sies H. Profiles of antioxidants in human plasma. Free Radic Biol Med 2001; 30: 456-62.
64. Mecocci P, Polidori MC, Troiano L, et al. Plasma antioxidants and longevity: a study on healthy centenarians. Free Radic Biol Med. 2000; 28: 1243-8.
65. Polidori MC, Mariani E, Baggio G, et al. Different antioxidant profiles in italian centenarians: the Sardinian peculiarity. Eur J Clin Nutr 2007; 61: 922-4.
66. Polidori MC, Praticó D, Mangialasche F, et al. High fruit and vegetable intake is positively correlated with antioxidant status and cognitive performance in healthy subjects. J Alzheimers Dis 2009; 17: 921-7.
67. Morris MC, Evans DA, Tangney CC, Bienias JL, Wilson RS. Associations of vegetable and fruit consumption with age-related cognitive change. Neurology 2006; 67: 1370-6.
68. Barberger-Gateau P, Raffaitin C, Letenneur L, et al. Dietary patterns and risk of dementia. Neurology 2007; 69: 1921-30.
69. Scarmeas N, Stern Y, Mayeaux R, Luchsinger GA. Mediterranean diet, Alzheimer disease, and vascular mediation, Arch Neurol 2006; 63; 1709-17.
70. Scarmeas N, Stern Y, Tang MX, Mayeux R, Luchsinger JA. Mediterranean diet and the risk for Alzheimer's disease. Ann Neurol 2006; 59: 912-21.
71. Scarmeas N, Luchsinger JA, Mayeux R, Stern Y. Mediterranean diet and Alzheimer's disease mortality. Neurology 2007; 69: 1084-93.
72. Vercambre MN, Grodstein F, Berr C, Kang JH. Mediterranean diet and cognitive decline in women with cardiovascular disease or risk factors. J Acad Nutr Diet 2012; 112: 816-23.
73. Burgener SC, Buettner L, Coen Buckwalter K, et al. Evidence supporting nutritional interventions for persons in early stage Alzheimer's disease. J Nutr Health Aging 2008; 12: 18-21.
74. Feng-Jiao L, Shen L, Ji HF. Dietary intakes of vitamin E, vitamin C and β-carotene and risk of Alzheimer's disease: A meta-analysis. J Alzheimer's dis 2012; 31: 253-58.